U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -1.53 (-2.86%)
     
  • Gold

    1,827.70
    -23.70 (-1.28%)
     
  • Silver

    24.83
    -0.97 (-3.77%)
     
  • EUR/USD

    1.2085
    -0.0079 (-0.6526%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3583
    -0.0057 (-0.4143%)
     
  • USD/JPY

    103.8000
    -0.0420 (-0.0404%)
     
  • BTC-USD

    34,894.51
    -106.15 (-0.30%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

·2 min read

NEW YORK, NY / ACCESSWIRE / January 8, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CounterPath Corporation (NASDAQ:CPAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Alianza, Inc. for $3.49 per share. If you are a CounterPath shareholder, click here to learn more about your rights and options.

HMS Holdings Corp. (NASDAQ:HMSY) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Gainwell Technologies for $37.00 in cash per share. If you are an HMS shareholder, click here to learn more about your rights and options.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Viracta Therapeutics, Inc. Sunesis stockholders are expected to own approximately 14% of the combined company on a fully diluted basis. If you are a Sunesis shareholder, click here to learn more about your rights and options.

Eidos Therapeutics, Inc. (NASDAQ:EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click here to learn more about your rights and options.

Halper Sadeh LLP may seek increased consideration, additional disclosures, and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060

sadeh@halpersadeh.com

zhalper@halpersadeh.com

https://www.halpersadeh.com

SOURCE: Halper Sadeh LLP



View source version on accesswire.com:
https://www.accesswire.com/623657/MERGER-INVESTIGATION-Halper-Sadeh-LLP-Investigates-CPAH-HMSY-SNSS-EIDX-Shareholders-Are-Encouraged-to-Contact-the-Firm